Sugi Predict

Sugi Predict / Compounds / SCHEMBL182871

SCHEMBL182871

SCHEMBL182871

O=c1[nH]cnc2ccc(Br)cc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 2/20 1.00
▸ PIM3 Q86V86 2/20 1.00
▸ CHEK1 O14757 1/20 1.00
▸ AKT1 P31749 1/20 1.00
▸ FLT3 P36888 1/20 1.00
▸ PARP1 P09874 8/20 0.64
▸ IP6K1 Q92551 8/20 0.58
▸ SLC2A1 P11166 1/20 0.57
▸ PDPK1 O15530 1/20 0.56
▸ CA12 O43570 1/20 0.56
▸ ALOX15 P16050 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.56
▸ CA9 Q16790 1/20 0.56
▸ TNKS2 Q9H2K2 1/20 0.56
▸ IP6K3 Q96PC2 5/20 0.54
▸ IP6K2 Q9UHH9 3/20 0.54
▸ CDC7 O00311 1/20 0.53
▸ CSNK2A2 P19784 1/20 0.53
▸ CSNK2B P67870 1/20 0.53
▸ CSNK2A1 P68400 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL29161413 0.98 PIM1 (0.96) PIM1PIM3CHEK1AKT1FLT3
SCHEMBL29440617 0.85 PIM1 (0.74) PIM1PIM3CHEK1AKT1FLT3
SCHEMBL391295 0.85 PIM1 (0.74) PIM1PIM3CHEK1AKT1FLT3
SCHEMBL8622180 0.81 ACVR1 (0.73) PIM1PIM3CHEK1AKT1FLT3
SCHEMBL7427860 0.79 IP6K1 (0.68) PIM1PIM3CHEK1AKT1FLT3
SCHEMBL216176 0.78 PARP1 (1.00) PIM1PIM3CHEK1AKT1FLT3
SCHEMBL642178 0.78 PARP1 (1.00) PIM1PIM3CHEK1AKT1FLT3
SCHEMBL2191067 0.78 PARP1 (1.00) PIM1PIM3CHEK1AKT1FLT3
SCHEMBL2081677 0.78 PARP1 (1.00) PIM1PIM3CHEK1AKT1FLT3
SCHEMBL29605527 0.78 PARP1 (1.00) PIM1PIM3CHEK1AKT1FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 318 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110655505-A 6- (2-amino-1H-benzo [ d ] imidazol-6-yl) quinazolin-4 (3H) -ones 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 2020-01-07 — — CN claimed
WO-2026102082-A1 ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE DEEP APPLE THERAPEUTICS, INC. (US) 2026-05-15 — — WO disclosed
US-12622909-B2 Allosteric EGFR inhibitors and methods of use thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2026-05-12 — — US disclosed
EP-4263518-B1 NEW QUINAZOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2026-04-01 — — EP disclosed
US-12570615-B2 Quinazolinone derivatives HOFFMANN-LA ROCHE INC. 2026-03-10 — — US disclosed
US-20260008770-A1 CBL-B INHIBITORS AND METHODS OF USES THEREOF INSILICO MEDICINE IP LTD (HK) 2026-01-08 — — US disclosed
EP-4647433-A1 SHP2 INHIBITOR AND USES THEREOF Kanaph Therapeutics Inc. (KR) 2025-11-12 — — EP disclosed
EP-4558504-A1 CBL-B INHIBITORS AND METHODS OF USES THEREOF Insilico Medicine IP Limited (HK) 2025-05-28 — — EP disclosed
WO-2025090514-A1 COVALENT SARM1 INHIBITORS NURA BIO, INC. (US) 2025-05-01 — — WO disclosed
CN-119630662-A CBL-B inhibitors and methods of use thereof 英矽智能科技知识产权有限公司 2025-03-14 — — CN disclosed
US-20040167198-A1 Vasculostatic agents and methods of use thereof TARGEGEN, INC. 2004-08-26 — — US disclosed
WO-2004030635-A2 VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF TARGEGEN, INC. (US) 2004-04-15 — — WO disclosed
WO-2003024448-A2 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE, INC. (CA) 2003-03-27 — — WO disclosed
US-20030018029-A1 Quinazoline derivatives ZENECA LIMITED 2003-01-23 — — US disclosed
US-6399602-B1 ANTICANCER AGENTS ZENECA LIMITED (GB) 2002-06-04 — — US disclosed
US-5866572-A RECEPTOR TYROSINE KINASE INHIBITORY PROPERTIES, TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER. ZENECA LIMITED (GB) 1999-02-02 — — US disclosed
EP-0880507-A1 QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS ZENECA LIMITED (GB) 1998-12-02 — — EP disclosed
WO-1997030034-A1 QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS ZENECA LIMITED (GB) 1997-08-21 — — WO disclosed
EP-0520722-B1 Therapeutic preparations containing quinazoline derivatives ZENECA LTD (GB) 1996-12-27 — — EP disclosed
EP-0520722-A1 Therapeutic preparations containing quinazoline derivatives ZENECA LIMITED (GB) 1992-12-30 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018029-A1 Quinazoline derivatives ABL1, FGFR1, ERBB2 PIM1 907/4885PIM3 1498/4885CHEK1 111/4885
US-20260008770-A1 CBL-B INHIBITORS AND METHODS OF USES THEREOF CBL, CBLC, CBLB PIM1 1974/4885PIM3 1695/4885CHEK1 463/4885
US-12622909-B2 Allosteric EGFR inhibitors and methods of use thereof EGFR, ERBB3, ERBB2 PIM1 1232/4885PIM3 874/4885CHEK1 553/4885
US-20040167198-A1 Vasculostatic agents and methods of use thereof RBP1, RBP4, VCAM1 PIM1 1381/4885PIM3 2192/4885CHEK1 2712/4885
US-12570615-B2 Quinazolinone derivatives ABL1, NQO2, CNR1 PIM1 2910/4885PIM3 2804/4885CHEK1 1159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.